169 related articles for article (PubMed ID: 33845308)
1. Positive interactions between STAP-1 and BCR-ABL influence chronic myeloid leukemia cell proliferation and survival.
Ishiura M; Kitai Y; Kashiwakura JI; Muromoto R; Toda J; Ichii M; Oritani K; Matsuda T
Biochem Biophys Res Commun; 2021 Jun; 556():185-191. PubMed ID: 33845308
[TBL] [Abstract][Full Text] [Related]
2. Signal-transducing adapter protein-1 is required for maintenance of leukemic stem cells in CML.
Toda J; Ichii M; Oritani K; Shibayama H; Tanimura A; Saito H; Yokota T; Motooka D; Okuzaki D; Kitai Y; Muromoto R; Kashiwakura JI; Matsuda T; Hosen N; Kanakura Y
Oncogene; 2020 Aug; 39(34):5601-5615. PubMed ID: 32661325
[TBL] [Abstract][Full Text] [Related]
3. STAP-2 interacts with and modulates BCR-ABL-mediated tumorigenesis.
Sekine Y; Ikeda O; Mizushima A; Ueno Y; Muromoto R; Yoshimura A; Kanakura Y; Oritani K; Matsuda T
Oncogene; 2012 Oct; 31(40):4384-96. PubMed ID: 22231445
[TBL] [Abstract][Full Text] [Related]
4. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
Hamilton A; Helgason GV; Schemionek M; Zhang B; Myssina S; Allan EK; Nicolini FE; Müller-Tidow C; Bhatia R; Brunton VG; Koschmieder S; Holyoake TL
Blood; 2012 Feb; 119(6):1501-10. PubMed ID: 22184410
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
[TBL] [Abstract][Full Text] [Related]
6. Bcr-abl regulates Stat5 through Shp2, the interferon consensus sequence binding protein (Icsbp/Irf8), growth arrest specific 2 (Gas2) and calpain.
Hjort EE; Huang W; Hu L; Eklund EA
Oncotarget; 2016 Nov; 7(47):77635-77650. PubMed ID: 27769062
[TBL] [Abstract][Full Text] [Related]
7. Src family kinases interfere with dimerization of STAT5A through a phosphotyrosine-SH2 domain interaction.
Fahrenkamp D; de Leur HS; Küster A; Chatain N; Müller-Newen G
Cell Commun Signal; 2015 Feb; 13():10. PubMed ID: 25885255
[TBL] [Abstract][Full Text] [Related]
8. Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia.
Waight JD; Banik D; Griffiths EA; Nemeth MJ; Abrams SI
J Biol Chem; 2014 May; 289(22):15642-52. PubMed ID: 24753251
[TBL] [Abstract][Full Text] [Related]
9. Blockade of Y177 and Nuclear Translocation of Bcr-Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells.
Li Q; Huang Z; Gao M; Cao W; Xiao Q; Luo H; Feng W
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257089
[TBL] [Abstract][Full Text] [Related]
10. CCR7 is involved in BCR-ABL/STAP-2-mediated cell growth in hematopoietic Ba/F3 cells.
Kubo K; Iwakami M; Muromoto R; Inagaki T; Kitai Y; Kon S; Sekine Y; Oritani K; Matsuda T
Biochem Biophys Res Commun; 2015 Aug; 463(4):825-31. PubMed ID: 26102025
[TBL] [Abstract][Full Text] [Related]
11. Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia.
Kollmann S; Grundschober E; Maurer B; Warsch W; Grausenburger R; Edlinger L; Huuhtanen J; Lagger S; Hennighausen L; Valent P; Decker T; Strobl B; Mueller M; Mustjoki S; Hoelbl-Kovacic A; Sexl V
Leukemia; 2019 Jul; 33(7):1583-1597. PubMed ID: 30679796
[TBL] [Abstract][Full Text] [Related]
12. Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells.
Grumbach IM; Mayer IA; Uddin S; Lekmine F; Majchrzak B; Yamauchi H; Fujita S; Druker B; Fish EN; Platanias LC
Br J Haematol; 2001 Feb; 112(2):327-36. PubMed ID: 11167825
[TBL] [Abstract][Full Text] [Related]
13. Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells.
Chatain N; Ziegler P; Fahrenkamp D; Jost E; Moriggl R; Schmitz-Van de Leur H; Müller-Newen G
Oncogene; 2013 Aug; 32(31):3587-97. PubMed ID: 22926520
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
[TBL] [Abstract][Full Text] [Related]
15. STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia.
Warsch W; Grundschober E; Berger A; Gille L; Cerny-Reiterer S; Tigan AS; Hoelbl-Kovacic A; Valent P; Moriggl R; Sexl V
Oncotarget; 2012 Dec; 3(12):1669-87. PubMed ID: 23458731
[TBL] [Abstract][Full Text] [Related]
16. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
[TBL] [Abstract][Full Text] [Related]
17. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
[TBL] [Abstract][Full Text] [Related]
18. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R
Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533
[TBL] [Abstract][Full Text] [Related]
20. Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway.
Wang X; Yang J; Guo G; Feng R; Chen K; Liao Y; Zhang L; Sun L; Huang S; Chen JL
Mol Cancer; 2019 Apr; 18(1):84. PubMed ID: 30961617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
